Video Experimental Relacionado
Updated: Sep 9, 2025

05:49
Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish
Published on: May 5, 2021
5.0K
La metformina puede alterar el curso de la neuropatía óptica hereditaria de Leber: un informe de caso
Shenoda Abd Elmaseh1, Danielle A Gauthier1,2, Maryam Golmohammadi1,2
1Department of Ophthalmology, David Geffen School of Medicine, Los Angeles, CA, United States.
Frontiers in medicine
|September 4, 2025
Resumen
La metformina mejoró la visión en un Leber
Área de la Ciencia:
- Genética mitocondrial y neuro-oftalmología.
- Investigando las raras neuropatías ópticas hereditarias.
- Explorando nuevas intervenciones terapéuticas para la pérdida de visión.
Sus antecedentes:
- La neuropatía óptica hereditaria de Leber (LHON) es una enfermedad del ADN mitocondrial (ADNm) heredada por la madre.
- Se caracteriza por la pérdida progresiva de la visión bilateral, que afecta principalmente a los varones jóvenes.
- Los tratamientos actuales como la idebenona ofrecen beneficios modestos para la función mitocondrial y la agudeza visual.
Objetivo del estudio:
- Para reportar un caso único de manejo de LHON en una paciente.
- Investigar la eficacia potencial de la metformina en un paciente que no responde a las terapias estándar.
- Para resaltar la necesidad de una mayor investigación sobre el papel de la metformina en la LHON.
Principales métodos:
- Estudio de caso de una mujer de 48 años diagnosticada con LHON (m.11778G>A/MT-ND4) y diabetes mellitus tipo 2.
- Pérdida progresiva de la visión documentada durante 26 meses a pesar de los tratamientos que incluyen idebenona, NAD+ y THS.
- Monitoreo de los cambios en el campo visual después de la introducción del tratamiento con metformina.
Principales resultados:
- El paciente experimentó una mejora significativa del campo visual después de 26 meses de pérdida progresiva de la visión.
- Esta mejora se produjo tras el tratamiento con metformina, tras el fracaso de idebenona, NAD+ y THS.
- El caso sugiere un beneficio potencial de la metformina en el manejo de LHON, particularmente en casos complejos.
Conclusiones:
- La metformina demostró una eficacia potencial en la mejora de los campos visuales en un paciente con LHON que no respondió a otros tratamientos.
- Este caso ofrece una perspectiva interesante sobre las estrategias de gestión alternativas para LHON.
- Son cruciales más investigaciones moleculares y clínicas para comprender el mecanismo de la metformina en la LHON.
Videos de Conceptos Relacionados
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Open Angle Glaucoma: Treatment
554
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
554
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Dipeptidyl Peptidase 4 Inhibitors
249
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
249
Photoreceptors and Visual Pathways
6.5K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
6.5K
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256

